Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
AbbVie’s new hepatitis C treatment candidate, a one tablet combination of the investigational drugs glecaprevir and pibrentasvir, harnessed the infection in all patients who completed a Japanese study. The treatment, ... Read more
Gilead Sciences’ Vemlidy (tenofovir alafenamide) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic hepatitis B virus (HBV) infection with compensated ... Read more
Preventing virus-triggered changes in human metabolic processes might become a future way to stymie viral infections, according to a recent study by an international group of scientists at the Hebrew University of Jerusalem. ... Read more
The proinflammatory cytokine IL-17 drives the development of non-alcoholic steatohepatitis, or NASH — a disease that often leads to liver cancer, researchers at the National Cancer Research Centre (CNIO), in Spain, ... Read more
A discovery of the process by which the hepatitis B virus matures inside the body helps to explain why the virus is much more potent that others in causing infection, and how it so effectively ... Read more